Qualigen Therapeutics, Inc. (QLGN) - Dilution Analysis

10-Q filing | 20.2M shares outstanding

8-K filing: AIxCrypto Holdings, Inc. reports amendments to entrusted investment agreements and a securities purchase agreement involving Faraday Future Intelligent Electric Inc. (FFAI), including the purchase of FFAI Class A Common Stock and Series C Convertible Preferred Stock by GOLD KING ARTHUR HOLDING LIMITED (GKA). ($12.0M proceeds)

10-K filing | 20.2M shares outstanding

8-K filing: Qualigen Therapeutics, Inc. consummated its previously announced transactions to purchase $41,000,000 in cash including 337,432 shares of the Company's common stock and 17,783 shares of a newly created Series B Convertible Preferred Stock. ($18.54M proceeds)

8-K filing: Qualigen Therapeutics, Inc. entered into a Subscription Agreement for a private placement offering of common stock and Series B Convertible Preferred Stock with certain investors, including Faraday Future Intelligent Electric Inc., for $41,000,000.

S-1 filing: This prospectus relates to the resale from time to time by the selling stockholders named in this prospectus of up to 3,214,292 shares of our common stock, par value $0.001 per share, issuable upon conversion of 4,500 shares of Series A-3 preferred stock held directly or indirectly by the Selling Stockholders.

10-Q filing | 1.7M shares outstanding

10-Q filing | 1.6M shares outstanding

10-K filing | 1.6M shares outstanding

S-1 filing: This S-1 filing relates to the resale of common stock underlying Series A-2 preferred stock by selling stockholders.

8-K filing: Qualigen Therapeutics, Inc. sold 5,100 shares of Series A-2 Preferred Stock at $1,000 per share in a private placement for $5.1 million and issued 1,154 shares of Series A-2 Convertible Preferred Stock in exchange for Chen's $1,100,000 principal amount convertible notes. ($5.1M proceeds)

10-Q filing | 0.7M shares outstanding

8-K filing: Stock split 1-for-50 | Outstanding: 12,155,830 → 736,431

S-1 filing: The company is offering up to 14,000,000 shares of common stock and pre-funded warrants to purchase up to 14,000,000 shares of common stock on a reasonable best efforts basis, with the offering terminating no later than October 31, 2024, unless fully subscribed or terminated earlier.

8-K filing: Qualigen Therapeutics, Inc. closed a public offering of 14,724,058 shares of common stock at $0.13 per share and pre-funded warrants to purchase up to 11,972,754 Shares at $0.129 per share, receiving aggregate gross proceeds of $3.47 million before fees and expenses. ($3.46M proceeds)

S-1/A filing: The company is offering up to $4 million of shares of common stock and pre-funded warrants on a reasonable best efforts basis, with Univest Securities, LLC acting as the exclusive placement agent.

10-Q filing | 12.2M shares outstanding

S-1/A filing: The company is offering common stock and pre-funded warrants to purchase common stock, with Univest Securities, LLC acting as the exclusive placement agent. The offering is on a "reasonable best efforts" basis, with the possibility of multiple closings by August 30, 2024, and may terminate earlier if fully subscribed or terminated at the company's discretion.

S-1/A filing: The company is offering up to $4,000,000 of shares of common stock and pre-funded warrants on a reasonable best efforts basis. The pre-funded warrants are exercisable for one share of common stock with an exercise price of $0.001 per share.

10-Q filing | 9.6M shares outstanding

S-1/A filing: The company is filing an S-1/A form and is offering shares of common stock, common stock warrants, and pre-funded warrants, with Univest Securities, LLC acting as the exclusive placement agent.

POS AM filing: This POS AM filing relates to the resale of common stock issuable upon conversion of a convertible debenture and exercise of a warrant by the selling stockholder.

8-K filing: Alpha Capital Anstalt exercised an option to purchase debentures and warrants, and Yi Hua Chen also exercised an option to purchase debentures and warrants. ($1.0M proceeds)

10-K filing | 6.3M shares outstanding

8-K filing: Qualigen Therapeutics, Inc. entered into a Securities Purchase Agreement with Alpha Capital Anstalt to issue an 8% Convertible Debenture and a warrant to purchase shares of common stock.

10-Q filing | 5.1M shares outstanding

S-1/A filing: This S-1/A filing relates to an offering that includes common stock, pre-funded warrants, and common stock warrants. The pre-funded warrants are exercisable at a nominal price of $0.001 per share, and the common stock warrants have a five-year term. The exercise price for the common stock warrants is not specified.

POS AM filing: This prospectus relates to the resale of up to 3,958,537 shares of common stock by the selling stockholder, which may be issued pursuant to the terms of a Senior Convertible Debenture and warrant.

10-Q filing | 5.1M shares outstanding

8-K filing: Qualigen Therapeutics sold all issued and outstanding shares of its subsidiary to Chembio Diagnostics for $5.1 million net purchase price and amended the Master Funding Agreement with Nanosynex, surrendering 281,000 Preferred B Shares of Nanosynex.

S-1 filing: This S-1 filing includes information on Qualigen Therapeutics' common stock, pre-funded warrants, and common stock warrants.

10-Q filing | 5.0M shares outstanding

10-K filing | 5.1M shares outstanding

S-3 filing: This S-3 filing relates to the resale of up to 5,157,087 shares of common stock by a selling stockholder, which may be issuable pursuant to the terms of a convertible debenture and warrant.

8-K filing: Qualigen Therapeutics, Inc. entered into a Securities Purchase Agreement with Alpha Capital Anstalt, issuing an 8% Senior Convertible Debenture in the aggregate principal amount of $3,300,000 for a purchase price of $3,000,000 and a common stock purchase warrant to purchase up to 2,500,000 shares of common stock.

8-K filing: Stock split 1-for-10 | Outstanding: 39,444,058 → 3,944,405

10-Q filing | 39.4M shares outstanding

10-Q filing | 36.7M shares outstanding

S-3 filing: Qualigen Therapeutics, Inc. is offering up to $150,000,000 of any combination of common stock, preferred stock, and debt securities from time to time.

S-3 filing: This S-3 filing registers for resale 8,161,312 shares of common stock, consisting of 3,500,000 shares of common stock and 4,661,312 shares issuable upon exercise of warrants, held by selling stockholders. The company will not receive any proceeds from the sale of these shares.

8-K filing: Qualigen Therapeutics, Inc. closed a transaction with NanoSynex Ltd. acquiring Series B preferred shares and entered into a Funding Agreement. Also closed a transaction with Alpha Capital Anstalt, acquiring Series A-1 preferred shares of NanoSynex in exchange for Qualigen common stock and a pre-funded warrant. ($0.6M proceeds)

10-Q filing | 35.3M shares outstanding

8-K filing: Qualigen Therapeutics, Inc. entered into a Series B Preferred Share Purchase Agreement with NanoSynex Ltd. to acquire Series B preferred shares, and a Share Purchase Agreement with Alpha Capital Anstalt to acquire Series A-1 preferred shares of NanoSynex in exchange for Qualigen common stock and pre-funded warrants. ($0.6M proceeds)

10-K filing | 35.3M shares outstanding

8-K filing: Qualigen Therapeutics, Inc. closed its Securities Purchase Agreement on December 1, 2021, issuing and selling 5,880,000 shares of common stock at $1.50 per share for gross proceeds of $8,820,000. ($8.82M proceeds)

10-Q filing | 29.1M shares outstanding

10-Q filing | 29.0M shares outstanding

8-K filing: The company amended its bylaws to add a new section pertaining to forum selection and elected Tariq Arshad as Senior Vice President and Chief Medical Officer, granting him 100,000 stock options with a $1.80 exercise price and the potential for an additional 300,000 options.

10-Q filing | 28.8M shares outstanding

8-K filing: Qualigen Therapeutics, Inc. closed a sale of 2,370,786 shares of common stock, 1,000,000 pre-funded warrants, 1,348,314 two-year warrants, and 842,696 warrants for gross proceeds of $12,000,000 on December 18, 2020. ($12.0M proceeds)

10-Q filing | 23.1M shares outstanding

8-K filing: Qualigen, Inc. filed a prospectus supplement for the proposed offer and sale of up to 4,731,203 shares of common stock upon future exercise of Series C Warrants.

10-Q filing | 21.0M shares outstanding

8-K filing: Qualigen Therapeutics sold 1,717,106 shares of common stock and warrants to purchase 1,287,829 shares to a single institutional investor for $10,000,000 on August 2, 2020, with the closing occurring on August 4, 2020. ($10.0M proceeds)

8-K filing: Qualigen Therapeutics closed a Securities Purchase Agreement, selling 1,140,570 shares of common stock and warrants for gross proceeds of $8,000,000. ($8.0M proceeds)

8-K filing: Qualigen Therapeutics, Inc. entered into a Securities Purchase Agreement for the sale of 1,200,000 shares of common stock, 780,198 pre-funded warrants, and 1,980,198 two-year warrants for $8,000,000 in a registered direct public offering expected to close on or about July 10, 2020. ($24.0M proceeds)

8-K filing: Qualigen Therapeutics, Inc. completed a reverse merger with Qualigen, Inc., implemented a 1-for-25 reverse stock split, and closed a private placement of Series Alpha Preferred Stock, while also issuing shares and warrants to GreenBlock Capital LLC for services rendered. ($4.01M proceeds)

10-Q filing | 45.7M shares outstanding

10-K filing | 6.0M shares outstanding

8-K filing: Ritter Pharmaceuticals entered into private exchange agreements to issue 826,919 shares of common stock in exchange for warrants, and combined with a previous filing, the total shares issued are 1,980,763.

8-K filing: Ritter Pharmaceuticals, Inc. entered into private exchange agreements with certain Warrant Holders to issue 1,153,844 shares of common stock in exchange for warrants to purchase the same amount of shares at $1.30 per share.